Clinical and prognostic features of spinal meningioma: a thorough analysis from a single neurosurgical center

Hua, Lingyang; Zhu, Hongda; Deng, Jiaojiao; Tian, Mi; Jiang, Xuewei; Tang, Hailiang; Luan, Shihai; Wakimoto, Hiroaki; Xie, Qing; Gong, Yi

doi:10.1007/s11060-018-2993-3

Cited by 42 publications

(55 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recurrence status cannot be completely predicted by histopathologic grade alone, as it is mainly based on histopathological characterizations of mitotic rate, cellular features of atypia, and local invasion (18). Meningiomas are well-known for their female-biased predominance (19), but tumors in male patients demonstrate not only a higher annual growth rate (20) but also a higher probability of recurrence (21)(22)(23). Previous studies have proposed molecular markers for prognostic scoring systems in recent years (14,21,(24)(25)(26), and a better WHO classification of meningiomas integrated with independent molecular markers may help to predict the recurrence risk and adjust treatment plans for patients with meningiomas.…”

Section: Introductionmentioning

confidence: 99%

High Copy-Number Variation Burdens in Cranial Meningiomas From Patients With Diverse Clinical Phenotypes Characterized by Hot Genomic Structure Changes

Hong

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Meningiomas, as the most common primary tumor of the central nervous system, are known to harbor genomic aberrations that associate with clinical phenotypes. Here we performed genome-wide genotyping for cranial meningiomas in 383 Chinese patients and identified 9,821 copy-number variations (CNVs). Particularly, patients with diverse clinical features had distinct tumor CNV profiles. CNV burdens were greater in high-grade (WHO grade II and III) samples, recurrent lesions, large tumors (diameter >4.3 cm), and those collected from male patients. Nevertheless, the level of CNV burden did not relate to tumor locations, peritumoral brain edema, bone invasion, or multiple lesions. Overall, the most common tumor CNVs were the copy-number gain (CNG) at 22q11.1 and the copy-number losses (CNLs) at 22q13.2, 14q11.2, 1p34.3, and 1p31.3. Recurrent lesions were featured by the CNLs at 1p31.3, 6q22.31, 9p21.3, and 11p12, and high-grade samples had more CNVs at 4q13.3 and 6q22.31. Meanwhile, large tumors were more likely to have the CNVs at 1p31.3 and 1p34.3. Additionally, recurrence prediction indicated the CNLs at 4p16.3 (p = 0.009, hazard ratio = 5.69) and 10p11.22 (p = 0.037, hazard ratio = 4.53) were candidate independent risk factors.

show abstract

Section: Introductionmentioning

confidence: 99%

High Copy-Number Variation Burdens in Cranial Meningiomas From Patients With Diverse Clinical Phenotypes Characterized by Hot Genomic Structure Changes

Hong

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…An initial review of the literature describing several large surgical studies of sporadic meningiomas (NF2-associated tumor studies are more rare and usually underpowered) indicated that the mean age at surgery for sporadic cranial meningiomas was between 53.8 and 58.3 y.o. [14][15][16][17] and the mean age at surgery for sporadic spinal meningiomas was between 53.0 and 69.0 y.o. [17][18][19][20][21] .…”

Section: Discussionmentioning

confidence: 99%

“…[14][15][16][17] and the mean age at surgery for sporadic spinal meningiomas was between 53.0 and 69.0 y.o. [17][18][19][20][21] . In one study, in which both cranial (N = 9,806) and spinal (N = 483) tumors were operated on at the same Table 3.…”

Section: Discussionmentioning

confidence: 99%

Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas

Pemov

Dewan

Hansen

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Neurofibromatosis type 2 (NF2) is an autosomal dominant Mendelian tumor predisposition disorder caused by germline pathogenic variants in the tumor suppressor NF2. Meningiomas are the second most common neoplasm in NF2, often occurring in multiple intracranial and spinal locations within the same patient. In this prospective longitudinal study, we assessed volumes and growth rates of ten spinal and ten cranial benign meningiomas in seven NF2 patients that concluded with surgical resection and performed whole-exome sequencing and copy-number variant (CNV) analysis of the tumors. Our comparison of the volume and the growth rate of NF2-associated spinal and cranial meningiomas point to the differences in timing of tumor initiation and/or to the differences in tumor progression (e.g., non-linear, saltatory growth) at these two anatomical locations. Genomic investigation of these tumors revealed that somatic inactivation of NF2 is the principal and perhaps the only driver of tumor initiation; and that tumor progression likely occurs via accumulation of CNVs, rather than point mutations. Results of this study contribute to a better understanding of NF2associated meningiomas clinical behavior and their genetic underpinnings. Neurofibromatosis type 2 (NF2) is a rare hereditary neoplasia syndrome, with an estimated incidence of 1:25,000-1:33,000 1,2. Although the hallmark and primary definitive diagnostic criterion of NF2 is the presence of bilateral vestibular schwannomas, meningiomas are the next most frequently identified tumor in these patients 3,4. It is estimated that 45-58% of NF2 patients harbor intracranial meningiomas and 20% have spinal meningiomas 5-7. Meningiomas in NF2 are typically WHO grade 1, slow-growing, benign tumors. When present, meningiomas in NF2 patients are often multiple, which contributes significantly to morbidity and mortality. Although symptoms are primarily due to the direct mass effect of tumor upon adjacent brain and cranial nerves, tumors may also evoke seizures and obstruct venous outflow causing cerebral edema 6. A case series examining 287 cranial meningiomas from NF2 patients confirmed that similar to their sporadic counterparts, the majority of NF2-associated meningiomas (95.8%) were grade 1 by WHO guidelines. Although only 4.2% of total meningiomas were grade 2 or 3, 35% of growing or symptomatic resected meningiomas were grade 2/3. Growth rate was generally slow, although 7.3% of meningiomas examined by MRI analysis displayed an annual volumetric growth rate of 20% or higher 8. The cumulative burden of intracranial meningiomas in NF2 patients results in a 2.51-fold greater risk of mortality when compared to NF2 patients without intracranial meningiomas 9 .

show abstract

“…На менингиомы спинного мозга приходится от 25% до 46% от всех первичных экстрамедуллярных спинальных опухолей и от 7% до 12,7% от всех менингиом центральной нервной системы. Заболевание в 0,34-2,5 раза чаще проявляется у женщин, чем у мужчин, притом в 85-90% случаев -в возрасте 50-70 лет [2,4,5]. Изучение эпидемиологии спинальных опухолей в Канаде показало, что до 30,7% всех интрадуральных опухолей спинного мозга составляют менингиомы.…”

unclassified

“…Тотальное удаление таких опухолей, в подавляющей своей массе носящих доброкачественный характер, приводит в большинстве случаев к выздоровлению больных, но нередко -в 4-31% случаев -они рецидивируют вновь, что значительно ухудшает качество жизни оперированных [5,8,9]. Столь высокие цифры рецидивирования спинальных менингиом и значительный статистический разброс в появлении случаев рецидивов связаны, в первую очередь, с субъективизмом при определении степени радикальности выполненных оперативных вмешательств.…”

unclassified

Reccurence and Continuous Grow of Spinal Menengiomas

Eliseenko¹,

Struts²,

Kalinichev³

et al. 2020

СПНО (MPSE)

View full text Add to dashboard Cite

На основании клинических данных у оперированных больных с менингиомами спинного мозга изучить частоту их рецидивирования и продолженного роста. Изучены и систематизированы результаты хирургического лечения двух групп пациентов (177 человек) с менингиомами спинного мозга, прооперированных в период 1998-2013 гг. в ФГБУ «Новосибирский научно-исследовательский институт травматологии и ортопедии им. Я.Л. Цивьяна» Минздрава России. Больным первой группы (группа сравнения, n=103, 58,19%) удаление опухолей выполнялось с применением стандартной микрохирургической техники, остальным пациентам (группа исследования, n=74, 41,81%) при резекции новообразования дополнительно использовалось излучение неодимового лазера. Тотально удалено менингиом-164 (92,66%), субтотально-13 (7,34%). В группе с использованием неодимового лазера тотально-73 (98,65%) из 74, субтотально-1 (1,35%). При использовании стандартной микрохирургической техники 91 (88,35%) новообразование из 103 удалено тотально, и 12 (11,65%)-субтотально (P>0,01). Рецидивы и продолженный рост диагностированы у 13 (7,4%) человек, из них у 6 (3,4%) наблюдался рецидив, а у 7 (3,9%)-продолженный рост. В группе сравнения у 11 (10,7%) человек отмечены рецидивы и продолженный рост опухолей. В случаях их тотального удаления рецидивов возникло 4 (3,9%), при субтотальном у 7 (6,7%) из 11 больных диагностирован продолженный рост новообразования. У оперированных с использованием лазерных технологий из 73 человек после тотального удаления опухоли выявлено 2 (2,7%) рецидива (Р=0,04). Разработанные лазерные технологии снижают вероятность возникновения рецидивов и продолженного роста и могут быть использованы при микрохирургическом удалении менингиом спинного мозга. Ключевые слова: менингиомы спинного мозга, рецидивы, продолженный рост, экстрамедуллярные опухоли, отдаленные результаты, неодимовый лазер.

show abstract

Clinical and prognostic features of spinal meningioma: a thorough analysis from a single neurosurgical center

Cited by 42 publications

References 26 publications

High Copy-Number Variation Burdens in Cranial Meningiomas From Patients With Diverse Clinical Phenotypes Characterized by Hot Genomic Structure Changes

High Copy-Number Variation Burdens in Cranial Meningiomas From Patients With Diverse Clinical Phenotypes Characterized by Hot Genomic Structure Changes

Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas

Reccurence and Continuous Grow of Spinal Menengiomas

Contact Info

Product

Resources

About